Nichotherapy for stem cells: There goes the neighborhood

BioEssays

Volumn 35, Issue 3, 2013, Pages 183-190

  Levesque, Jean Pierre ^a   Winkler, Ingrid G ^a   Rasko, John E J ^b,c  

^a MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^b CENTENARY INSTITUTE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bone marrow niche; Granulocyte colony stimulating factor; Leukemia; Mobilization; Plerixafor; Stem cell

Indexed keywords

COLONY STIMULATING FACTOR;

ARTICLE; BONE MARROW; BONE REGENERATION; CANCER THERAPY; HEMATOPOIETIC STEM CELL; LEUKEMIA; NICHOTHERAPY; STEM CELL; STEM CELL MOBILIZATION;

ANIMALS; BONE MARROW CELLS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; NEOPLASMS; STEM CELL NICHE;

EID: 84873545307     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201200111     Document Type: Article

References (100)

1. Schofield R. 1978. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 4: 7-25.
2. Lymperi S, Ferraro F, Scadden DT. 2010. The HSC niche concept has turned 31. Has our knowledge matured? Ann N Y Acad Sci 1192: 12-8.
3. To LB, Levesque J-P, Herbert KE. 2011. How I treat patients who mobilize hematopoietic stem cells poorly. Blood 118: 4530-40.
4. Magee JA, Piskounova E, Morrison SJ. 2012. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21: 283-96.
5. Joyce JA, Pollard JW. 2009. Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-52.
6. Bissell MJ, Hines WC. 2011. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17: 320-9.
7. Raaijmakers MHGP. 2011. Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system. Haematologica 96: 1041-8.
8. Cabarcas SM, Mathews LA, Farrar WL. 2011. The cancer stem cell niche - there goes the neighborhood? Int J Cancer 129: 2315-27.
9. Ishikawa F, Yoshida S, Saito Y, Hijikata A, et al. 2007. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25: 1315-21.
10. Iwamoto S, Mihara K, Downing JR, Pui C-H, et al. 2007. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 117: 1049-57.
11. Lane SW, Scadden DT, Gilliland DG. 2009. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 114: 1150-7.
12. Butler JM, Gars EJ, James DJ, Nolan DJ, et al. 2012. Development of a vascular niche platform for expansion of repopulating human cord blood stem and progenitor cells. Blood 120: 1344-7.
13. Sacchetti B, Funari A, Michienzi S, Di Cesare S, et al. 2007. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131: 324-36.
14. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, et al. 2010. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466: 829-34.
15. Ding L, Saunders TL, Enikolopov G, Morrison SJ. 2012. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 481: 457-62.
16. Calvi LM, Adams GB, Weibrecht KW, Weber JM, et al. 2003. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425: 841-6.
17. Raaijmakers MHGP, Mukherjee S, Guo S, Zhang S, et al. 2010. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464: 852-7.
18. Visnjic D, Kalajzic Z, Rowe DW, Katavic V, et al. 2004. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 103: 3258-64.
19. Butler JM, Nolan DJ, Vertes EL, Varnum-Finney B, et al. 2010. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 6: 251-64.
20. Yamazaki S, Ema H, Karlsson G, Yamaguchi T, et al. 2011. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone narrow niche. Cell 147: 1146-58.
21. Winkler IG, Sims NA, Pettit AR, Barbier V, et al. 2010. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 116: 4815-28.
22. Ludin A, Itkin T, Gur-Cohen S, Mildner A, et al. 2012. Monocytes-macrophages that express alpha-smooth muscle actin preserve primitive hematopoietic cells in the bone marrow. Nat Immunol 13: 1072-82.
23. Kiel MJ, Morrison SJ. 2008. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol 8: 290-301.
24. Trumpp A, Essers M, Wilson A. 2010. Awakening dormant haematopoietic stem cells. Nat Rev Immunol 10: 201-9.
25. Wilson A, Laurenti E, Oser G, van der Wath RC, et al. 2008. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 135: 1118-29.
26. Winkler IG, Barbier V, Nowlan B, Jacobsen RN, et al. 2012. Vascular niche E-selectin regulate hematopoietic stem cell dormancy, self-renewal and chemoresistance. Nat Med, in press, DOI: 10.1038/nm.2969.
27. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, et al. 2005. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121: 1109-21.
28. Lo Celso C, Fleming HE, Wu JW, Zhao CX, et al. 2009. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 457: 92-7.
29. Xie Y, Yin T, Wiegraebe W, He XC, et al. 2009. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 457: 97-101.
30. Sugiyama T, Kohara H, Noda M, Nagasawa T. 2006. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25: 977-88.
31. Winkler IG, Barbier V, Wadley R, Zannettino ACW, et al. 2010. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood 116: 375-85.
32. Branemark P-I. 1961. Experimental investigation of microcirculation in bone marrow. Angiology 12: 293-305.
33. Levesque J-P, Winkler IG, Hendy J, Williams B, et al. 2007. Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1α and vascular endothelial growth factor A in bone marrow. Stem Cells 25: 1954-65.
34. Parmar K, Mauch P, Vergilio J-A, Sackstein R, et al. 2007. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 104: 5431-6.
35. Takubo K, Goda N, Yamada W, Iriuchishima H, et al. 2010. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell 7: 391-402.
36. Christopher MJ, Rao M, Liu F, Woloszynek JR, et al. 2011. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med 208: 251-60.
37. + macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med 208: 261-71.
38. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, et al. 2003. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 111: 187-96.
39. Levesque JP, Hendy J, Winkler IG, Takamatsu Y, et al. 2003. Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells. Exp Hematol 31: 109-17.
40. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, et al. 2001. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 98: 1289-97.
41. Winkler IG, Levesque JP. 2006. Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone. Exp Hematol 34: 996-1009.
42. Katayama Y, Battista M, Kao WM, Hidalgo A, et al. 2006. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 124: 407-21.
43. Levesque JP, Helwani FM, Winkler IG. 2010. The endosteal "osteoblastic" niche and its role in hematopoietic stem cell homing and mobilization. Leukemia 24: 1979-92.
44. Ratajczak MZ, Lee H, Wysoczynski M, Wan W, et al. 2010. Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia 24: 976-85.
45. Golan K, Vagima Y, Ludin A, Itkin T, et al. 2012. S1P promotes murine progenitor cell egress and mobilization via S1P1-mediated ROS signaling and SDF-1 release. Blood 119: 2478-88.
46. Larsen SR, Chng K, Battah F, Martiniello-Wilks R, et al. 2008. Improved granulocyte colony-stimulating factor mobilization of hemopoietic progenitors using cytokine combinations in primates. Stem Cells 26: 2974-80.
47. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, et al. 2005. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201: 1307-18.
48. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, et al. 2009. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 27: 4767-73.
49. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, et al. 2009. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113: 5720-6.
50. Adams GB, Martin RP, Alley IR, Chabner KT, et al. 2007. Therapeutic targeting of a stem cell niche. Nat Biotechnol 25: 238-43.
51. Takamatsu Y, Simmons PJ, Moore RJ, Morris HA, et al. 1998. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood 92: 3465-73.
52. Ballen KK, Shpall EJ, Avigan D, Yeap BY, et al. 2007. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant 13: 838-43.
53. Holst J, Watson S, Lord MS, Eamegdool SS, et al. 2010. Substrate elasticity provides mechanical signals for the expansion of hemopoietic stem and progenitor cells. Nat Biotechnol 28: 1123-8.
54. Bonnet D, Dick JE. 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-7.
55. Kennedy JA, Barabe F, Poeppl AG, Wang JC, et al. 2007. Comment on "tumor growth need not be driven by rare cancer stem cells." Science 318: 1722; author reply 1722.
56. Tang M, Gonen M, Quintas-Cardama A, Cortes J, et al. 2011. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood 118: 1622-31.
57. Marcucci G, Haferlach T, Döhner H. 2011. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 29: 475-86.
58. Yates J, Glidewell O, Wiernik P, Cooper MR, et al. 1982. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60: 454-62.
59. Lowenberg B, Pabst T, Vellenga E, van Putten W, et al. 2011. Cytarabine dose for acute myeloid leukemia. N Engl J Med 364: 1027-36.
60. Burnett A, Wetzler M, Löwenberg B. 2011. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29: 487-94.
61. Ninomiya M, Abe A, Katsumi A, Xu J, et al. 2006. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 21: 136-42.
62. Nervi B, Ramirez P, Rettig MP, Uy GL, et al. 2009. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113: 6206-14.
63. Zeng Z, Shi YX, Samudio IJ, Wang R-Y, et al. 2009. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113: 6215-24.
64. + leukemia. Cancer Cell 19: 740-53.
65. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, et al. 2011. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121: 1298-312.
66. Sun YX, Schneider A, Jung Y, Wang J, et al. 2005. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 20: 318-29.
67. Huang EH, Singh B, Cristofanilli M, Gelovani J, et al. 2009. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 155: 231-6.
68. Muller A, Homey B, Soto H, Ge N, et al. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-6.
69. Sloan EK, Pouliot N, Stanley KL, Chia J, et al. 2006. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 8: R20.
70. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, et al. 2012. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481: 85-9.
71. Schuettpelz LG, Link DC. 2011. Niche competition and cancer metastasis to bone. J Clin Invest 121: 1253-5.
72. Sun Y, Campisi J, Higano C, Beer TM, et al. 2012. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med, in press, DOI: 10.1038/nm.2890.
73. Erler JT, Bennewith KL, Cox TR, Lang G, et al. 2009. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15: 35-44.
74. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, et al. 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-7.
75. Eckhardt BL, Francis PA, Parker BS, Anderson RL. 2012. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 11: 479-97.
76. Ben-Neriah Y, Karin M. 2011. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 12: 715-23.
77. Qian B, Deng Y, Im JH, Muschel RJ, et al. 2009. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 4: e6562.
78. Pucci F, Venneri MA, Biziato D, Nonis A, et al. 2009. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 114: 901-14.
79. Bonde AK, Tischler V, Kumar S, Soltermann A, et al. 2012. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer 12: 35.
80. Kawata M, Koinuma D, Ogami T, Umezawa K, et al. 2012. TGF-beta-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells. J Biochem 151: 205-16.
81. Sangaletti S, Di Carlo E, Gariboldi S, Miotti S, et al. 2008. Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res 68: 9050-9.
82. Cheng P, Corzo CA, Luetteke N, Yu B, et al. 2008. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 205: 2235-49.
83. Marigo I, Bosio E, Solito S, Mesa C, et al. 2010. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 32: 790-802.
84. Qian BZ, Pollard JW. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
85. Abraham D, Zins K, Sioud M, Lucas T, et al. 2010. Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma. Int J Cancer 126: 1339-52.
86. Lucas T, Abraham D, Untergasser G, Zins K, et al. 2009. Adenoviral-mediated endothelial precursor cell delivery of soluble CD115 suppresses human prostate cancer xenograft growth in mice. Stem Cells 27: 2342-52.
87. Paulus P, Stanley ER, Schafer R, Abraham D, et al. 2006. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res 66: 4349-56.
88. Jinushi M, Chiba S, Yoshiyama H, Masutomi K, et al. 2011. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci USA 108: 12425-30.
89. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, et al. 2011. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 96: 269-76.
90. Steidl C, Lee T, Shah SP, Farinha P, et al. 2010. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362: 875-85.
91. Brooke G, Tong H, Levesque JP, Atkinson K. 2008. Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev 17: 929-40.
92. Homeister JW, Thall AD, Petryniak B, Maly P, et al. 2001. The alpha(1, 3)fucosyltransferases FucT-IV and FucT-VII exert collaborative control over selectin-dependent leukocyte recruitment and lymphocyte homing. Immunity 15: 115-26.
93. Frenette PS, Subbarao S, Mazo IB, von Andrian UH, et al. 1998. Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow. Proc Natl Acad Sci USA 95: 14423-8.
94. Sackstein R, Merzaban JS, Cain DW, Dagia NM, et al. 2008. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 14: 181-7.
95. Jacobsen K, Kravitz J, Kincade PW, Osmond DG. 1996. Adhesion receptors on bone marrow stromal cells: in vivo expression of vascular cell adhesion molecule-1 by reticular cells and sinusoidal endothelium in normal and gamma-irradiated mice. Blood 87: 73-82.
96. Grassinger J, Haylock DN, Storan MJ, Haines GO, et al. 2009. Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with {alpha}9{beta}1 and {alpha}4{beta}1 integrins. Blood 114: 49-59.
97. Rogers MJ. 2003. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9: 2643-58.
98. Guan M, Yao W, Liu R, Lam KS, et al. 2012. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med 18: 456-62.
99. Postovit LM, Margaryan NV, Seftor EA, Kirschmann DA, et al. 2008. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natl Acad Sci USA 105: 4329-34.
100. Ruiz-Vela A, Aguilar-Gallardo C, Simon C. 2009. Building a framework for embryonic microenvironments and cancer stem cells. Stem Cell Rev 5: 319-27.